Sanofi Steps Up To Lend A Hand Producing Pfizer/BioNTech's COVID-19 Vaccine In Europe
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.
You may also be interested in...
It’s counter-intuitive, but not signing a commercial contract with BioNTech and refusing US federal funding were two of several moves Pfizer made to speed up development of its COVID-19 vaccine, CEO Albert Bourla says. Now it’s looking to supply low- and middle-income countries.
The COVID-19 pandemic led to a marked increase in sales of Sanofi’s LMW heparin, Lovenox, in the first quarter of 2021. The big pharma is also nearing late-stage clinical studies with two COVID-19 vaccine candidates.
Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.